Analysts See $-0.01 EPS for Innovus Pharmaceuticals, Inc. (INNV) on April, 1

On April, 1 is expected Innovus Pharmaceuticals, Inc. (OTCMKTS:INNV)’s earnings report, RTT reports. Last year’s earnings per share was $-0.01, while now analysts expect change of 0.00 % from current $-0.01 earnings per share. Last quarter $-0.01 earnings per share was reported. Analysts forecasts 0.00 % EPS growth this quarter. Ticker’s shares touched $0.0517 during the last trading session after 12.39% change.Currently Innovus Pharmaceuticals, Inc. is after 0.00% change in last March 14, 2018. INNV has 30,000 shares volume. INNV underperformed by 4.37% the S&P 500.

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States.The firm is worth $12.66 million. The Company’s products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream that enhances penile sensitivity; Zestra Glide, a water longer lasting lubricant; Vesele, a proprietary oral supplement of Arginine sexual and cognitive functions; and Androferti, a natural supplement to support overall male reproductive health and sperm quality.Last it reported negative earnings. The firm also offers Beyond Human testosterone booster, Ketones, krill oil, Omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; and UriVarx, a proprietary supplement for overactive bladder and urinary incontinence.

For more Innovus Pharmaceuticals, Inc. (OTCMKTS:INNV) news released briefly go to: Seekingalpha.com, Seekingalpha.com, Seekingalpha.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Innovus Pharma acquires all of the assets of SupplementHunt.com – Seeking Alpha” released on December 14, 2018, “Innovus Pharmaceuticals acquires worldwide rights to four products from Boston Topicals – Seeking Alpha” on November 19, 2018, “Innovus Pharma’s UriVarx shows positive effect in overactive bladder study – Seeking Alpha” with a publish date: February 07, 2018, “Innovus Testosterone Booster capsules OK’d in Canada – Seeking Alpha” and the last “Innovus Pharma’ Diabasens OK’d in Canada – Seeking Alpha” with publication date: March 01, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.